Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
NuCana announces four poster presentations at ESMO Congress » 08:10
09/16/21
09/16
08:10
09/16/21
08:10
NCNA

NuCana

$2.40 /

+0.025 (+1.05%)

NuCana announced the…

NuCana announced the presentation of four posters at the European Society for Medical Oncology Congress 2021. The Company presented additional data from the ongoing Phase 1b/2 study of NUC-3373 in combination with standard therapies in patients with advanced colorectal cancer, final data from the Phase 1 study of NUC-3373 in patients with advanced solid tumors, and additional interim data from the Phase 1 study of NUC-7738 in patients with advanced solid tumors. The Company also presented a trials-in-progress poster describing the ongoing Phase 3 study of Acelarin plus cisplatin in patients with advanced biliary tract cancer. NuCana presented two posters on NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, one of the most widely used anti-cancer medicines. NUC-3373 has been designed to overcome the main challenges associated with 5-FU, including cancer-resistance mechanisms, the generation of toxic metabolites and unfavorable pharmacokinetics. Poster Title: A Phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer: This poster describes encouraging interim data from 38 patients with metastatic colorectal cancer. In this difficult-to-treat group, with patients having received a median of four prior lines of therapy, NUC-3373, with or without leucovorin, demonstrated encouraging signs of efficacy. In addition to several patients achieving a longer progression-free survival on NUC-3373 than they had on their prior therapy, tumor reductions were observed in three patients: one who experienced a 40% reduction in their target lesion and two others with 28% and 15% reductions, respectively, in overall tumor burden. NUC-3373 also demonstrated a favorable safety profile in this patient population with no FBAL or FUTP-associated Grade 3 or 4 toxicities, such as hand-foot syndrome, diarrhea or neutropenia. Based on these encouraging interim results, NuTide:302 has been expanded to a Phase 1b/2 study and now allows enrollment of less heavily pre-treated patients, including second-line colorectal cancer patients. A registrational study of NUC-3373 in second-line colorectal cancer patients is also planned. Poster Title: Final results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours: This poster highlights final results from the NuTide:301 study in patients with advanced solid tumors. NUC-3373 showed a favorable safety profile and encouraging anti-cancer activity, including in patients previously treated with 5-FU. Additionally, three patients achieved stable disease lasting at least 9 months. NUC-3373 demonstrated an attractive pharmacokinetic profile with a long plasma half-life of between 6 and 14 hours compared to 8 to 14 minutes for 5-FU. Furthermore, NUC-3373 generated approximately 300 times higher levels of the active anti-cancer metabolite, FUDR-MP, than 5-FU. The recommended Phase 2 monotherapy dose of NUC-3373 was established at 2,500mg/m2. NUC-7738, a ProTide transformation of a novel anti-cancer nucleoside analog, 3'-deoxyadenosine, has multiple potential anti-cancer mechanisms of action and is being evaluated in a Phase 1 study in patients with advanced solid tumors who have exhausted all standard therapies. Poster Title: A first-in-human study of NUC-7738, a ProTide transformation of 3'-deoxyadenosine, in patients with advanced solid tumors: This poster describes interim data from the ongoing Phase 1 study and the data demonstrate NUC-7738's encouraging anti-cancer activity in multiple tumor-types. NUC-7738 has been well tolerated with no Grade 3 or 4 treatment-related adverse events and no dose-limiting toxicities. The ProTide generated high levels of the key anti-cancer metabolite, 3'-dATP, which had a prolonged intracellular half-life and was still detectable after 50 hours. Three case studies were described detailing two patients with metastatic melanoma and one patient with metastatic lung adenocarcinoma who achieved reductions in the size of target lesions coupled with prolonged stable disease. Following treatment with NUC-7738, one patient with metastatic melanoma became eligible for surgery and their tumor was completely resected. Recruitment to the NuTide:701 study is ongoing and once the recommended Phase 2 dose has been established, NUC-7738 is expected to advance into the Phase 2 part of the study. Poster Title: Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer: This trial-in-progress poster highlights the Company's global multi-center, randomized Phase 3 study comparing Acelarin, a ProTide transformation of gemcitabine, in combination with cisplatin, to gemcitabine in combination with cisplatin in up to 828 patients with advanced biliary tract cancer who have not previously received treatment for advanced disease. Enrollment of 418 evaluable patients has been achieved and the first of three interim analyses is expected to occur in the first half of 2022. NuCana believes that a statistically significant improvement in the Objective Response Rate at the first interim analysis, accompanied by positive trends in other endpoints, has the potential to allow for accelerated approval of a new drug application (NDA) for Acelarin in the United States.

ShowHide Related Items >><<
NCNA NuCana
$2.40 /

+0.025 (+1.05%)

NCNA NuCana
$2.40 /

+0.025 (+1.05%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$2.40 /

+0.025 (+1.05%)

  • 17
    Sep
Wednesday
Hot Stocks
NuCana completed enrollment of patient in Phase III NuTide:121 study » 08:08
09/15/21
09/15
08:08
09/15/21
08:08
NCNA

NuCana

$2.38 /

-0.145 (-5.75%)

NuCana announced it has…

NuCana announced it has completed enrollment of the number of patients in the ongoing Phase III NuTide:121 study required to conduct the first interim analysis. The study, which is comparing Acelarin combined with cisplatin to the global standard of care, gemcitabine plus cisplatin, as a first-line treatment for patients with advanced biliary tract cancer, has enrolled 418 patients with measurable disease. The first interim analysis will be conducted after the 418th patient has completed 28 weeks of follow-up, which is expected to occur in the first half of 2022. NuCana believes that a statistically significant improvement in the Objective Response Rate at the first interim analysis, accompanied by positive trends in other endpoints, has the potential to allow for accelerated approval of a new drug application for Acelarin in the United States. Recruitment in the NuTide:121 study, which is intended to enroll up to 828 patients, is ongoing and NuCana believes subsequent analyses could provide the confirmatory data to support full approval. "We are very pleased to achieve this important enrollment milestone which brings us closer to our goal of developing more effective and safer medicines for patients with cancer," said Hugh Griffith, NuCana's Founder and Chief Executive Officer. "Biliary tract cancer is a devastating disease and there is a significant need for more effective medicines. We are especially grateful to all of the patients, their families, the investigators and other health care professionals involved in the NuTide:121 study. The primary objective of the first interim analysis is to demonstrate at least a 14% improvement in the ORR in the Acelarin plus cisplatin arm compared to the gemcitabine plus cisplatin arm. In the ABC-08 study of Acelarin plus cisplatin as a first-line treatment for patients with biliary tract cancer, an ORR of 44% was achieved among the evaluable population. This compared favorably to the ORR of 26% achieved among evaluable patients treated with gemcitabine plus cisplatin in the ABC-02 study, which established this regimen as the global standard of care. We look forward to announcing the outcome of this first interim analysis in the first half of 2022."

ShowHide Related Items >><<
NCNA NuCana
$2.38 /

-0.145 (-5.75%)

NCNA NuCana
$2.38 /

-0.145 (-5.75%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$2.38 /

-0.145 (-5.75%)

  • 17
    Sep
Over a week ago
Conference/Events
Citigroup to hold a virtual conference » 04:55
09/10/21
09/10
04:55
09/10/21
04:55
AVRO

Avrobio

$6.44 /

+0.09 (+1.42%)

, ERYP

Erytech Pharma

$6.17 /

-0.08 (-1.28%)

, HRMY

Harmony Biosciences

$37.88 /

-0.66 (-1.71%)

, QURE

uniQure

$35.41 /

+0.73 (+2.10%)

, RCKT

Rocket Pharmaceuticals

$34.47 /

+0.395 (+1.16%)

, XFOR

X4 Pharmaceuticals

$5.01 /

+0.16 (+3.30%)

, IPHA

Innate Pharma

$6.15 /

+0.23 (+3.89%)

, TSHA

Taysha Gene Therapies

$20.12 /

+0.27 (+1.36%)

, NMTR

9 Meters Biopharma

$1.33 /

-0.01 (-0.75%)

, MORF

Morphic

$60.64 /

-0.07 (-0.12%)

, NCNA

NuCana

$2.44 /

+0.025 (+1.04%)

, XCUR

Exicure

$1.40 /

+0.06 (+4.48%)

, CMMB

Chemomab Therapeutics

$14.50 /

-0.38 (-2.55%)

, LABP

Landos Biopharma

$15.43 /

+0.13 (+0.85%)

16th Annual BioPharma…

16th Annual BioPharma Virtual Conference to be held on September 8-10.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.01 /

+0.16 (+3.30%)

XCUR Exicure
$1.40 /

+0.06 (+4.48%)

TSHA Taysha Gene Therapies
$20.12 /

+0.27 (+1.36%)

RCKT Rocket Pharmaceuticals
$34.47 /

+0.395 (+1.16%)

QURE uniQure
$35.41 /

+0.73 (+2.10%)

NMTR 9 Meters Biopharma
$1.33 /

-0.01 (-0.75%)

NCNA NuCana
$2.44 /

+0.025 (+1.04%)

MORF Morphic
$60.64 /

-0.07 (-0.12%)

LABP Landos Biopharma
$15.43 /

+0.13 (+0.85%)

IPHA Innate Pharma
$6.15 /

+0.23 (+3.89%)

HRMY Harmony Biosciences
$37.88 /

-0.66 (-1.71%)

ERYP Erytech Pharma
$6.17 /

-0.08 (-1.28%)

CMMB Chemomab Therapeutics
$14.50 /

-0.38 (-2.55%)

AVRO Avrobio
$6.44 /

+0.09 (+1.42%)

AVRO Avrobio
$6.44 /

+0.09 (+1.42%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
ERYP Erytech Pharma
$6.17 /

-0.08 (-1.28%)

HRMY Harmony Biosciences
$37.88 /

-0.66 (-1.71%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
QURE uniQure
$35.41 /

+0.73 (+2.10%)

07/27/21 Chardan
uniQure price target lowered to $95 from $100 at Chardan
07/09/21 Chardan
uniQure coverage transferred at Chardan
06/23/21 Chardan
uniQure filing delay could yield better label for EtranaDez, says Chardan
06/16/21 Chardan
uniQure on track for 'powerful' Huntington's catalyst, says Chardan
RCKT Rocket Pharmaceuticals
$34.47 /

+0.395 (+1.16%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
XFOR X4 Pharmaceuticals
$5.01 /

+0.16 (+3.30%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
IPHA Innate Pharma
$6.15 /

+0.23 (+3.89%)

09/02/21 SVB Leerink
SVB Leerink 'encouraged' by Innate's COAST update, upgrades to Outperform
09/02/21 SVB Leerink
Innate Pharma upgraded to Outperform from Market Perform at SVB Leerink
12/15/20
Fly Intel: Top five analyst downgrades
12/15/20 SVB Leerink
Innate Pharma downgraded to Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$20.12 /

+0.27 (+1.36%)

08/17/21 Chardan
Taysha Gene Therapies price target lowered to $60 from $67.50 at Chardan
07/15/21 Needham
Taysha Gene Therapies initiated with a Buy at Needham
07/09/21 Chardan
Taysha Gene Therapies coverage transferred at Chardan
06/24/21 Truist
Truist starts Taysha Gene Therapies at Buy on potential de-risking events
NMTR 9 Meters Biopharma
$1.33 /

-0.01 (-0.75%)

07/08/21 BMO Capital
9 Meters Biopharma initiated with an Outperform at BMO Capital
06/04/21 Citi
9 Meters Biopharma initiated with a Buy at Citi
05/26/21 Truist
9 Meters' larazotide has potential application in syndrome, says Truist
03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
MORF Morphic
$60.64 /

-0.07 (-0.12%)

06/11/21 BMO Capital
Morphic coverage transferred at BMO Capital
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
NCNA NuCana
$2.44 /

+0.025 (+1.04%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
XCUR Exicure
$1.40 /

+0.06 (+4.48%)

06/11/21 BMO Capital
Exicure coverage transferred at BMO Capital
12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
CMMB Chemomab Therapeutics
$14.50 /

-0.38 (-2.55%)

05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
LABP Landos Biopharma
$15.43 /

+0.13 (+0.85%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
XFOR X4 Pharmaceuticals
$5.01 /

+0.16 (+3.30%)

XCUR Exicure
$1.40 /

+0.06 (+4.48%)

TSHA Taysha Gene Therapies
$20.12 /

+0.27 (+1.36%)

RCKT Rocket Pharmaceuticals
$34.47 /

+0.395 (+1.16%)

QURE uniQure
$35.41 /

+0.73 (+2.10%)

NMTR 9 Meters Biopharma
$1.33 /

-0.01 (-0.75%)

NCNA NuCana
$2.44 /

+0.025 (+1.04%)

MORF Morphic
$60.64 /

-0.07 (-0.12%)

LABP Landos Biopharma
$15.43 /

+0.13 (+0.85%)

HRMY Harmony Biosciences
$37.88 /

-0.66 (-1.71%)

CMMB Chemomab Therapeutics
$14.50 /

-0.38 (-2.55%)

AVRO Avrobio
$6.44 /

+0.09 (+1.42%)

  • 31
    Mar
  • 03
    Mar
  • 04
    Feb
  • 11
    Dec
  • 10
    Dec
  • 20
    Nov
  • 24
    Sep
  • 17
    Sep
XCUR Exicure
$1.40 /

+0.06 (+4.48%)

RCKT Rocket Pharmaceuticals
$34.47 /

+0.395 (+1.16%)

QURE uniQure
$35.41 /

+0.73 (+2.10%)

NMTR 9 Meters Biopharma
$1.33 /

-0.01 (-0.75%)

ERYP Erytech Pharma
$6.17 /

-0.08 (-1.28%)

CMMB Chemomab Therapeutics
$14.50 /

-0.38 (-2.55%)

XFOR X4 Pharmaceuticals
$5.01 /

+0.16 (+3.30%)

MORF Morphic
$60.64 /

-0.07 (-0.12%)

ERYP Erytech Pharma
$6.17 /

-0.08 (-1.28%)

Conference/Events
Citigroup to hold a virtual conference » 04:55
09/09/21
09/09
04:55
09/09/21
04:55
AVRO

Avrobio

$6.35 /

-0.01 (-0.16%)

, ERYP

Erytech Pharma

$6.25 /

-0.2 (-3.10%)

, HRMY

Harmony Biosciences

$38.44 /

+0.64 (+1.69%)

, QURE

uniQure

$34.68 /

-0.24 (-0.69%)

, RCKT

Rocket Pharmaceuticals

$34.07 /

-1.09 (-3.10%)

, XFOR

X4 Pharmaceuticals

$4.85 /

-0.14 (-2.81%)

, IPHA

Innate Pharma

$5.75 /

+0.1 (+1.77%)

, TSHA

Taysha Gene Therapies

$19.76 /

-1.81 (-8.39%)

, NMTR

9 Meters Biopharma

$1.34 /

+ (+0.00%)

, MORF

Morphic

$60.65 /

-3.715 (-5.77%)

, NCNA

NuCana

$2.42 /

-0.125 (-4.92%)

, XCUR

Exicure

$1.34 /

-0.02 (-1.48%)

, CMMB

Chemomab Therapeutics

$14.85 /

-0.15 (-1.00%)

, LABP

Landos Biopharma

$15.30 /

+0.88 (+6.10%)

16th Annual BioPharma…

16th Annual BioPharma Virtual Conference to be held on September 8-10.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

XCUR Exicure
$1.34 /

-0.02 (-1.48%)

TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

NCNA NuCana
$2.42 /

-0.125 (-4.92%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

IPHA Innate Pharma
$5.75 /

+0.1 (+1.77%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
QURE uniQure
$34.68 /

-0.24 (-0.69%)

07/27/21 Chardan
uniQure price target lowered to $95 from $100 at Chardan
07/09/21 Chardan
uniQure coverage transferred at Chardan
06/23/21 Chardan
uniQure filing delay could yield better label for EtranaDez, says Chardan
06/16/21 Chardan
uniQure on track for 'powerful' Huntington's catalyst, says Chardan
RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
IPHA Innate Pharma
$5.75 /

+0.1 (+1.77%)

09/02/21 SVB Leerink
SVB Leerink 'encouraged' by Innate's COAST update, upgrades to Outperform
09/02/21 SVB Leerink
Innate Pharma upgraded to Outperform from Market Perform at SVB Leerink
12/15/20
Fly Intel: Top five analyst downgrades
12/15/20 SVB Leerink
Innate Pharma downgraded to Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

08/17/21 Chardan
Taysha Gene Therapies price target lowered to $60 from $67.50 at Chardan
07/15/21 Needham
Taysha Gene Therapies initiated with a Buy at Needham
07/09/21 Chardan
Taysha Gene Therapies coverage transferred at Chardan
06/24/21 Truist
Truist starts Taysha Gene Therapies at Buy on potential de-risking events
NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

07/08/21 BMO Capital
9 Meters Biopharma initiated with an Outperform at BMO Capital
06/04/21 Citi
9 Meters Biopharma initiated with a Buy at Citi
05/26/21 Truist
9 Meters' larazotide has potential application in syndrome, says Truist
03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
MORF Morphic
$60.65 /

-3.715 (-5.77%)

06/11/21 BMO Capital
Morphic coverage transferred at BMO Capital
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
NCNA NuCana
$2.42 /

-0.125 (-4.92%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
XCUR Exicure
$1.34 /

-0.02 (-1.48%)

06/11/21 BMO Capital
Exicure coverage transferred at BMO Capital
12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

XCUR Exicure
$1.34 /

-0.02 (-1.48%)

TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

NCNA NuCana
$2.42 /

-0.125 (-4.92%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

  • 31
    Mar
  • 03
    Mar
  • 04
    Feb
  • 11
    Dec
  • 10
    Dec
  • 20
    Nov
  • 24
    Sep
  • 17
    Sep
XCUR Exicure
$1.34 /

-0.02 (-1.48%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

Conference/Events
Citigroup to hold a virtual conference » 17:24
09/08/21
09/08
17:24
09/08/21
17:24
AVRO

Avrobio

$6.35 /

-0.01 (-0.16%)

, ERYP

Erytech Pharma

$6.25 /

-0.2 (-3.10%)

, HRMY

Harmony Biosciences

$38.44 /

+0.64 (+1.69%)

, QURE

uniQure

$34.68 /

-0.24 (-0.69%)

, RCKT

Rocket Pharmaceuticals

$34.07 /

-1.09 (-3.10%)

, XFOR

X4 Pharmaceuticals

$4.85 /

-0.14 (-2.81%)

, IPHA

Innate Pharma

$5.75 /

+0.1 (+1.77%)

, TSHA

Taysha Gene Therapies

$19.76 /

-1.81 (-8.39%)

, NMTR

9 Meters Biopharma

$1.34 /

+ (+0.00%)

, MORF

Morphic

$60.65 /

-3.715 (-5.77%)

, NCNA

NuCana

$2.42 /

-0.125 (-4.92%)

, XCUR

Exicure

$1.34 /

-0.02 (-1.48%)

, CMMB

Chemomab Therapeutics

$14.85 /

-0.15 (-1.00%)

, LABP

Landos Biopharma

$15.30 /

+0.88 (+6.10%)

16th Annual BioPharma…

16th Annual BioPharma Virtual Conference to be held on September 8-10.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

XCUR Exicure
$1.34 /

-0.02 (-1.48%)

TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

NCNA NuCana
$2.42 /

-0.125 (-4.92%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

IPHA Innate Pharma
$5.75 /

+0.1 (+1.77%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
QURE uniQure
$34.68 /

-0.24 (-0.69%)

07/27/21 Chardan
uniQure price target lowered to $95 from $100 at Chardan
07/09/21 Chardan
uniQure coverage transferred at Chardan
06/23/21 Chardan
uniQure filing delay could yield better label for EtranaDez, says Chardan
06/16/21 Chardan
uniQure on track for 'powerful' Huntington's catalyst, says Chardan
RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
IPHA Innate Pharma
$5.75 /

+0.1 (+1.77%)

09/02/21 SVB Leerink
SVB Leerink 'encouraged' by Innate's COAST update, upgrades to Outperform
09/02/21 SVB Leerink
Innate Pharma upgraded to Outperform from Market Perform at SVB Leerink
12/15/20
Fly Intel: Top five analyst downgrades
12/15/20 SVB Leerink
Innate Pharma downgraded to Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

08/17/21 Chardan
Taysha Gene Therapies price target lowered to $60 from $67.50 at Chardan
07/15/21 Needham
Taysha Gene Therapies initiated with a Buy at Needham
07/09/21 Chardan
Taysha Gene Therapies coverage transferred at Chardan
06/24/21 Truist
Truist starts Taysha Gene Therapies at Buy on potential de-risking events
NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

07/08/21 BMO Capital
9 Meters Biopharma initiated with an Outperform at BMO Capital
06/04/21 Citi
9 Meters Biopharma initiated with a Buy at Citi
05/26/21 Truist
9 Meters' larazotide has potential application in syndrome, says Truist
03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
MORF Morphic
$60.65 /

-3.715 (-5.77%)

06/11/21 BMO Capital
Morphic coverage transferred at BMO Capital
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
NCNA NuCana
$2.42 /

-0.125 (-4.92%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
XCUR Exicure
$1.34 /

-0.02 (-1.48%)

06/11/21 BMO Capital
Exicure coverage transferred at BMO Capital
12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

XCUR Exicure
$1.34 /

-0.02 (-1.48%)

TSHA Taysha Gene Therapies
$19.76 /

-1.81 (-8.39%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

NCNA NuCana
$2.42 /

-0.125 (-4.92%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

LABP Landos Biopharma
$15.30 /

+0.88 (+6.10%)

HRMY Harmony Biosciences
$38.44 /

+0.64 (+1.69%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

AVRO Avrobio
$6.35 /

-0.01 (-0.16%)

  • 31
    Mar
  • 03
    Mar
  • 04
    Feb
  • 11
    Dec
  • 10
    Dec
  • 20
    Nov
  • 24
    Sep
  • 17
    Sep
XCUR Exicure
$1.34 /

-0.02 (-1.48%)

RCKT Rocket Pharmaceuticals
$34.07 /

-1.09 (-3.10%)

QURE uniQure
$34.68 /

-0.24 (-0.69%)

NMTR 9 Meters Biopharma
$1.34 /

+ (+0.00%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

CMMB Chemomab Therapeutics
$14.85 /

-0.15 (-1.00%)

XFOR X4 Pharmaceuticals
$4.85 /

-0.14 (-2.81%)

MORF Morphic
$60.65 /

-3.715 (-5.77%)

ERYP Erytech Pharma
$6.25 /

-0.2 (-3.10%)

Over a month ago
Syndicate
NuCana files $400M mixed securities shelf  16:51
08/19/21
08/19
16:51
08/19/21
16:51
NCNA

NuCana

$1.95 /

-0.06 (-2.99%)

 
ShowHide Related Items >><<
NCNA NuCana
$1.95 /

-0.06 (-2.99%)

NCNA NuCana
$1.95 /

-0.06 (-2.99%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$1.95 /

-0.06 (-2.99%)

  • 17
    Sep
Earnings
NuCana reports Q2 loss GBP(0.17) versus GBP (0.19) YoY » 16:07
08/19/21
08/19
16:07
08/19/21
16:07
NCNA

NuCana

$1.95 /

-0.06 (-2.99%)

As of June 30, NuCana had…

As of June 30, NuCana had cash and cash equivalents of GBP 73.4M compared to GBP 78.6M at March 31 and GBP 87.4M as of December 31. NuCana continues to advance its various clinical programs and reported a net loss of GBP 9.1M for the quarter ended June 30, as compared to a net loss of GBP 6.1M for the quarter ended June 30, 2020. Basic and diluted loss per share was GBP 0.17 for the quarter ended June 30, 2021, as compared to GBP 0.19 per share for quarter ended June 30, 2020. "It has been a productive first half of 2021 with our release of important non-clinical and clinical data announcements. These include data from the NuTide:302 Phase Ib study of NUC-3373 in patients with advanced colorectal cancer as well as from the NuTide:701 Phase I study of NUC-7738 in patients with advanced solid tumors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "These data presentations, made at several medical conferences, continue to support the favorable clinical profile we have observed to date and the broad potential of our ProTide technology." Mr. Griffith continued: "As we look ahead to the second half of the year, we anticipate presenting additional clinical data from NUC-3373 and NUC-7738. Despite the COVID-19 pandemic, we remain on track to recruit sufficient patients in 2021 in the ongoing NuTide:121 Phase III clinical study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer to enable the first interim analysis in 2022. We are hopeful that this could enable us to submit an NDA in the United States under the FDA's accelerated approval program. We are also on track with other key milestones, including the initiation this year of a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer."

ShowHide Related Items >><<
NCNA NuCana
$1.95 /

-0.06 (-2.99%)

NCNA NuCana
$1.95 /

-0.06 (-2.99%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$1.95 /

-0.06 (-2.99%)

  • 17
    Sep
Hot Stocks
NuCana appoints Jeffrey Bloss as Chief Medical Officer » 08:21
08/10/21
08/10
08:21
08/10/21
08:21
NCNA

NuCana

$2.26 /

+0.21 (+10.24%)

NuCana announced the…

NuCana announced the appointment of Jeffrey Bloss, M.D. as Chief Medical Officer. Bloss will be based in NuCana's US offices located outside Boston, MA. Jeffrey Bloss, M.D. brings over 25 years of leadership experience in oncology at multiple biopharmaceutical companies including Astellas, GlaxoSmithKline, Xencor, Onyx, Genentech and Eli Lilly.

ShowHide Related Items >><<
NCNA NuCana
$2.26 /

+0.21 (+10.24%)

NCNA NuCana
$2.26 /

+0.21 (+10.24%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$2.26 /

+0.21 (+10.24%)

  • 17
    Sep
Conference/Events
NuCana management to meet virtually with Oppenheimer » 04:55
08/05/21
08/05
04:55
08/05/21
04:55
NCNA

NuCana

$2.01 /

-0.06 (-2.90%)

Virtual Meetings to be…

Virtual Meetings to be held on August 3-5 hosted by Oppenheimer.

ShowHide Related Items >><<
NCNA NuCana
$2.01 /

-0.06 (-2.90%)

NCNA NuCana
$2.01 /

-0.06 (-2.90%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$2.01 /

-0.06 (-2.90%)

  • 17
    Sep
Conference/Events
NuCana management to meet virtually with Oppenheimer » 04:55
08/04/21
08/04
04:55
08/04/21
04:55
NCNA

NuCana

$2.07 /

-0.055 (-2.59%)

Virtual Meetings to be…

Virtual Meetings to be held on August 3-5 hosted by Oppenheimer.

ShowHide Related Items >><<
NCNA NuCana
$2.07 /

-0.055 (-2.59%)

NCNA NuCana
$2.07 /

-0.055 (-2.59%)

01/15/21 Piper Sandler
Piper sees more evidence that NuCana's NUC-3373 'a better 5-FU'
12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
NCNA NuCana
$2.07 /

-0.055 (-2.59%)

  • 17
    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.